ATOS
Atossa TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ATOS Profile
Atossa Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions
Pharmaceutical
04/30/2009
11/08/2012
NASDAQ Stock Exchange
13
12-31
Common stock
10202 5th Avenue NE, Suite 200, Seattle, WA 98125
--
Atossa Therapeutics, Inc., was incorporated in Delaware on April 30, 2009. They are a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines in the areas of significant unmet medical needs in oncology and infectious diseases, currently focusing on breast cancer, other breast conditions and COVID 19. The drug they are developing to treat breast cancer and other breast diseases is Endoxifen, which is mainly developed in two cases: one is to reduce tumor cell activity in breast cancer patients during the "window of opportunity" between breast cancer diagnosis and surgery; the other is suitable for women with dense breast tissue to reduce density. The two COVID 19 drugs they are developing are AT-H201, which is used to improve lung function in moderately to severely hospitalized COVID 19 patients by inhalation; and AT-301, a nasal spray for COVID 19 patients to use at home. Their business strategy is to advance their projects through clinical research, including partners, and opportunistically add projects in areas of unmet medical need through acquisitions, collaborations or in-house development.
